7 recruiting, 5 active not recruiting, 2 completed. 14 Phase 3.
By phase and status
Follow LOU064: new trials by email Literature Review of LOU064 trials Research Report on LOU064
Trials (filtered) newest first · largest first
All 14 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO) Remibrutinib, Placebo - Chronic Pruritus of Unknown Origin | Phase 3 | Recruiting | 180 | 2026-10-07 | 2026-11-09 |
Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks Remibrutinib, Omalizumab - Chronic Spontaneous Urticaria | Phase 3 | Recruiting | 382 | 2026-09-21 | 2026-11-09 |
A 52-week Study of Remibrutinib in IgE-mediated Food Allergy Remibrutinib, Placebo - IgE-Mediated Food Allergy, Peanut Allergy | Phase 3 | Recruiting | 576 | 2026-08-27 | 2026-11-09 |
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO) Remibrutinib, Placebo - Chronic Pruritus of Unknown Origin | Phase 3 | Recruiting | 180 | 2026-08-24 | 2026-11-09 |
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS Remibrutinib - Hidradenitis Suppurativa | Phase 3 | Recruiting | 710 | 2026-07-10 | 2026-11-09 |
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis Remibrutinib (blinded), Placebo, Remibrutinib (Open label) - Secondary Progressive Multiple Sclerosis (SPMS) | Phase 3 | Recruiting | 1275 | 2025-11-11 | 2026-10-13 |
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. Remibrutinib oral treatment, Ocrelizumab - Relapsing Multiple Sclerosis | Phase 3 | Recruiting | 400 | 2025-06-23 | 2026-10-26 |
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1 - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | 565 | 2025-03-20 | 2026-10-15 |
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis Remibrutinib (Blinded), Placebo, Remibrutinib (Open Label) - Generalized Myasthenia Gravis | Phase 3 | Active not recruiting | 180 | 2025-02-07 | 2026-09-28 |
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1 - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | 588 | 2025-01-31 | 2026-10-15 |
A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks. LOU064 - Chronic Spontaneous Urticaria | Phase 3 | Completed | 144 | 2023-04-05 | 2025-10-16 |
A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines LOU064 - Chronic Spontaneous Urticaria | Phase 3 | Completed | 71 | 2022-01-15 | 2025-04-08 |
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1) Remibrutinib, Teriflunomide - Relapsing Multiple Sclerosis | Phase 3 | Active not recruiting | 1000 | 2021-12-16 | 2026-08-18 |
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) Remibrutinib, Teriflunomide - Relapsing Multiple Sclerosis | Phase 3 | Active not recruiting | 1007 | 2021-12-13 | 2026-11-12 |
Conditions studied
Chronic Urticaria (3) · Hidradenitis Suppurativa (3) · Charcot-Marie-Tooth disease, Type 1F (2) · Dermatitis (2) · Hidradenitis (2) · Recurrence (2) · Egg Hypersensitivity (1) · Food Hypersensitivity (1) · Milk Hypersensitivity (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Chronic Progressive (1) · Myasthenia Gravis (1) · Peanut Hypersensitivity (1)
Sponsors
Novartis Pharmaceuticals (14)
Countries
United States (12) · Canada (11) · Argentina (10) · Spain (9) · Germany (8) · China (7) · France (7) · Italy (7) · Poland (7) · Mexico (6) · Slovakia (6) · United Kingdom (6) · Australia (5) · Brazil (5) · Czechia (5)
Results publications
PMID 41712058, PMID 42915009
NIH funding
2023 (3), 2025 (3)